Categories: All postsAnalysts

Espial Group has a 113 per cent upside, Mackie Research says

Espial Group (Espial Group Stock Quote, Chart TSX:ESP) reported fourth quarter financials on Thursday, with Mackie Research analyst Nikhil Thadani saying that the video software company is taking it one step at a time.

Q4 revenue of $6.7 million was slightly above Thadani’s $6.4 million estimate but below the consensus $7.0, while adjusted EPS of $0.03 was better than expected.

ESP was down 43 per cent over 2018 but Thadani says that the stock should benefit as investors gain comfort in the company’s subscription model transition and a successful return to top line growth in 2019.

“While the stock may decline in the near term as 2019 consensus gets revised a bit lower, the stock is likely closer to its floor,” says Thadani in a client update on Friday. “ESP is down approx. seven per cent since Q3 results in November. Further downside may not be as pronounced as it has been in the past twelve months. Q4 results last night were more or less in-line with our estimates.”

“More importantly, ESP’s cash balance, which should help provide a floor for the stock price, recovered nicely quarter-over-quarter as we expected and per comments on the Q3 earnings call. That said, it appears ESP will invest to grow its subscription revenue in 2019, which could lead to more modest 2019 EBITDA and possibly some quarters just below EBITDA break-even. We walked back our higher 2019 revenue growth expectations, which we modelled after Q3 results. We also expect 2019 consensus to be lowered a bit,” he says.

Thadani has lowered his 2019 estimates from revenue and EBITDA of $29.3 million and $2.5 million, respectively, to $28.6 million and $1.1 million, respectively. His new 2020 forecast calls for revenue of $32.4 million and EBITDA of $4.5 million.

Thadani is maintaining his “Buy” rating and $2.60 target price, representing a projected return of 113 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: esp
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is MDP stock a buy? (June, 2024)

Following a new development, Echelon Capital Markets analyst Stefan Quenneville has raised his price target on Medexus Pharmaceuticals (Medexus Pharmaceuticals… [Read More]

4 hours ago

CVO price target chopped at National Bank

Following the company's fourth quarter results, National Bank Financials analyst Richard Tse has cut his price target on Coveo Solutions… [Read More]

5 hours ago

Is D2L stock a buy? (June, 2024)

Its first quarter results have been put to bed and Eight Capital analyst Christian Sgro remains bullish on D2L (D2L… [Read More]

1 day ago

Sell your AMC stock, Roth says

After updating his financial model on AMC, Roth MKM analyst Eric Handler remains bearish on AMC (AMC Stock Quote, Chart,… [Read More]

1 day ago

CIBC raises price target on Stingray Group

Following the company's fourth quarter results, CIBC analyst Scott Fletcher has raised his price target on Stingray Group (Stingray Group… [Read More]

1 day ago

Is LOOP stock still a buy? (June, 2024)

Its fourth quarter results are in the books and Paradigm Capital analyst J. Marvin Wolff still thinks there is money… [Read More]

2 days ago